Thank you for visiting the Astellas Pharma Inc. Website.
You will enter external sites beyond here.
(This link opens in a new window)
Important Notice
This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site.
Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
I Agree
Financial Information
Review our consolidated business results, forecasts and financial data, etc.
IR Library
This section contains IR related information for shareholders and investors. Various IR materials can be downloaded from here.
IR Calendar
Find our upcoming IR events.
Stock & Rating Information
Year-end dividend - March 31 Interim dividend - September 30 Note: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment.
Analyst Coverage
List of analysts of securities companies and research companies who make recommendations and reports of Astellas' performance, etc
Cautionary Statement
The information disclosed in this part of the Astellas Website is provided for better understanding of Astellas by stakeholders including shareholders and investors, but is intended to neither solicit nor recommend the purchase of the Astellas's stock.
Corporate Information
Let us introduce our company profile, such as company name, capital and office locations.
Vision & Strategy
On the forefront of healthcare change to turn innovative science into value for patients.
Pipeline
We introduce the progress of our clinical development projects called "R&D pipeline". We update R&D pipeline 4 or 5 times annually in our quarterly performance reports.